Context
Medios is a leading provider of high-priced complex specialty pharma products and individualized Patient-Specific Therapies in Germany
The company covers all relevant aspects of the supply chain: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal individualized patient care via specialized pharmacies
Medios announced on 25th November 2021 a purchase agreement to acquire NewCo Pharma GmbH at a €125m EV. NewCo Pharma is one of the leading regional Patient-Specific Therapy providers in Western and South-Western Germany with EUR 153m in revenues (2020) and growing double-digit
The transformative and highly-synergistic acquisition of NewCo Pharma enables Medios to significantly strengthen the higher-margin segment of Patient-Specific Therapies, making Medios the undisputed leader in Germany. The Group Patient-Specific Therapies revenues, EBITDA and annual preparation output will immediately triple while the expansion of Medios’ network of partner pharmacies and product offering represents significant cross-selling opportunities
This acquisition gives Medios a solid basis and the means to expand outside of Germany and also into new product categories
Proceeds from the offering will be used to finance the cash component for the acquisition of the NewCo Pharma Group
About Medios
Medios AG is the leading provider of Specialty Pharma solutions in Germany. As a competence partner and expert, Medios covers all relevant aspects of the supply chain in this field: from pharmaceutical supply to the manufacture of patient-specific therapies including blistering. The focus is on optimal patient care via specialized pharmacies.
Medios AG is Germany's first listed Specialty Pharma company. The shares (ISIN: DE000A1MMCC8) are listed on the Regulated Market of the Frankfurt Stock Exchange (Prime Standard).
Deal Team
Should you want to know more about this transaction, you can contact one of the team members above
Bryan, Garnier & Co acts as Lead Joint Bookrunner to leading German Specialty Pharmaceuticals provider Medios AG on its EUR 93 million Follow-on Offering
Acting as Lead Joint Bookrunner, Bryan Garnier helped raise EUR 93m for Medios AG in an oversubscribed follow-on offering on Frankfurt Stock Exchange
In light of strong and high-quality book of demand, the offering was upsized from EUR 72m to EUR 93m and priced at a very limited discount of 4.2% in the midst of a volatile market environment due to the Omicron variant outbreak
Bryan Garnier brought demand into the book from a mix of tier-1 long-only healthcare specialists and growth generalists as well as a handful of hedge funds. Final Bryan Garnier allocations were 70% geared towards Long-Only and HC specialists
Prior to the transaction, Bryan Garnier organized a very targeted NDR with c.25 investors across continental Europe, the UK and the US, most of which were new to the company, and assisted Medios in refining its equity story and the best way to articulate and present the acquisition rationale and synergies
This is Bryan, Garnier & Co’s 13th European Healthcare capital increase in 2021 and the 4th on the German market, demonstrating Bryan, Garnier & Co’s unique ability to raise capital for European healthcare companies in a highly competitive fundraising environment
Share